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Abstract 
Background: Kidney transplantation is the most effective treatment for end-stage renal disease. Sensitization refers 
to pre-existing antibodies against human leukocyte antigen (HLA) protein and remains a major barrier to successful 
transplantation. Despite implementation of desensitization strategies, many candidates fail to respond. Our objective 
was to determine whether measuring B cell repertoires could differentiate candidates that respond to desensitization 
therapy.
Methods: We developed an assay based on high-throughput DNA sequencing of the variable domain of the heavy 
chain of immunoglobulin genes to measure changes in B cell repertoires in 19 highly HLA-sensitized kidney trans-
plant candidates undergoing desensitization and 7 controls with low to moderate HLA sensitization levels. Respond-
ers to desensitization had a decrease of 5% points or greater in cumulated calculated panel reactive antibody (cPRA) 
levels, and non-responders had no decrease in cPRA.
Results: Dominant B cell clones were not observed in highly sensitized candidates, suggesting that the B cells 
responsible for sensitization are either not present in peripheral blood or present at comparable levels to other cir-
culating B cells. Candidates that responded to desensitization therapy had pre-treatment repertoires composed of a 
larger fraction of class-switched (IgG and IgA) isotypes compared to non-responding candidates. After B cell depleting 
therapy, the proportion of switched isotypes increased and the mutation frequencies of the remaining non-switched 
isotypes (IgM and IgD) increased in both responders and non-responders, perhaps representing a shift in the reper-
toire towards memory B cells or plasmablasts. Conversely, after transplantation, non-switched isotypes with fewer 
mutations increased, suggesting a shift in the repertoire towards naïve B cells.
Conclusions: Relative abundance of different B cell isotypes is strongly perturbed by desensitization therapy and 
transplantation, potentially reflecting changes in the relative abundance of memory and naïve B cell compartments. 
Candidates that responded to therapy experienced similar changes to those that did not respond. Further studies are 
required to understand differences between these two groups of highly sensitized kidney transplant candidates.
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Background
Kidney transplantation is the most effective form of 
therapy for end-stage renal disease (ESRD) in terms 
of mortality, quality of life and health care savings [1]. 
Human leukocyte antigen (HLA) sensitization is a major 
barrier to successful kidney transplantation, especially 
amongst the highly sensitized. Sensitized kidney trans-
plant candidates comprise approximately 30% of the 
deceased donor waiting list and have the longest wait 
times because of difficulty in finding a compatible donor 
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against human HLA proteins that are produced in the 
transplant candidate after contact with non-self HLA 
antigens, commonly from previous transplants, preg-
nancies and blood transfusions [3–5]. Antigen-specific 
B cells recognize, bind, internalize and process the anti-
gens through the B cell receptor (BCR) [6]. When a co-
stimulatory signal is present from CD4+ T cells, B cells 
undergo clonal expansion, producing plasmablasts, 
which secrete high affinity HLA antibodies, and memory 
B cells, which can provide a source of HLA antibodies 
long after the sensitizing event [6].
Desensitization therapies include plasmapheresis, 
which physically removes proteins from sera, intravenous 
immunoglobulin (IVIG), which can decrease circulating 
HLA antibody proteins, anti-CD20 monoclonal antibody 
treatment (rituximab), which depletes most B cells with 
the notable exception of antibody-producing plasma 
cells, and proteasome inhibitors (bortezomib), which 
target plasma cells. Candidates who respond to desensi-
tization therapy with a decrease in HLA antibodies and 
undergo successful transplantation show a survival ben-
efit compared to remaining on dialysis [7, 8]. However, 
for unknown reasons, circulating HLA antibody levels do 
not decrease in a significant number of sensitized kidney 
transplant candidates following desensitization therapy, 
and potential toxicity from medications could lead to 
unwarranted risk and poor outcomes. The degree of sen-
sitization to individual donor HLA proteins is measured 
using single antigen bead assays. Defining HLA matching 
at the epitope level may allow for a more detailed assess-
ment of HLA compatibility by addressing the immuno-
genicity of a particular HLA antigen mismatch [9]. This 
information is crucial for matching donated organs with 
transplant candidates, but it is not informative as to 
which sensitized candidates will respond to desensitiza-
tion therapy [10, 11].
Genomic rearrangement of variable (V), diversity 
(D) and joining (J) segments of immunoglobulin genes 
generates a diverse set of BCRs that recognize different 
antigens [12, 13]. Most of the diversity in the antibody 
repertoire is in the hypervariable complementarity-
determining region 3 (CDR3) of the heavy chain of the 
BCR and largely accounts for antibody specificity [14]. 
The constant region determines the antibody isotype. 
Naïve B cells produce both IgM and IgD isotypes. After 
encountering antigen, B cells undergo clonal expansion 
and somatic hypermutation, affinity maturation, and 
class-switch recombination to produce IgG, IgA or IgE 
antibodies [15]. High-throughput DNA sequencing of 
immunoglobulin genes has been used to detect and fol-
low residual disease in B cell malignancies, determine 
vaccine response, and perhaps has a role in autoimmune 
disease diagnostics [16–20]. We reported that repertoire 
sequencing is correlated with immune activity during 
rejection episodes in heart transplant recipients [21].
Investigations of HLA sensitization may benefit from B 
cell immune repertoire sequencing because the antigen 
is known and several therapies that target B cells and/or 
decrease HLA antibodies are available. We developed an 
assay utilizing high-throughput DNA sequencing of the 
variable domain of the antibody heavy chain of immuno-
globulin genes to measure changes in B cell repertoires 
before and after desensitization therapy and transplanta-
tion. Our objective was to survey a small cohort of highly 
sensitized kidney transplant candidates to determine 
whether measuring baseline and longitudinal B cell rep-
ertoires could serve as early biomarkers to help select 
candidates that will respond to therapy.
Methods
Kidney transplant candidates
19 highly HLA-sensitized candidates with ESRD and 
cumulative calculated panel reactive antibody (cPRA) 
scores of 93–100% were treated with desensitization 
therapy. Eleven candidates responded to therapy and 
received transplants (“responders”) whereas eight did not 
respond to therapy (“non-responders”). After more than 
6  months of desensitization therapy without a decrease 
in HLA antibodies, three non-responders (N-03, N-05 
and N-06) received well-matched transplants. They 
remained non-responders in our analysis based on lack 
of a response to therapy. Candidates were enrolled in the 
protocol based on waiting time on the deceased donor 
kidney transplant list or availability of an incompatible 
living donor. Seven additional candidates with ESRD and 
cPRA scores of 0–41% who received transplants served 
as controls (Fig. 1). Age, sex, race, cause of ESRD, cPRA 
values before and after therapy, response to therapy and 
transplantation status are summarized in Table  1 and 
Additional file  1: Table S1. Written informed consent 
was obtained from all candidates. The consent included 
HIPPAA authorization for access to medical records. 
The Institutional Review Board at Stanford University 
approved the protocol (15267 and 17997).
HLA antibody measurements
cPRA is the traditional measurement for the degree of 
sensitization in transplant candidates [2, 22]. cPRA is an 
index of the probability of finding a compatible donor 
and is based on HLA antibody specificities and strength 
detected in the serum combined with the frequency of 
those HLA antigens in the donor population. Therefore, 
cPRA estimates the percentage of donors with whom a 
candidate would be incompatible with a score of 0% indi-
cating no existing HLA antibodies and a good chance of 
receiving a matched organ and a score of 100% indicating 
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multiple, high strength antibodies to common HLA 
alleles and thus almost no chance of finding a match. 
Candidates with a cPRA score of 80% or more are consid-
ered highly sensitized [23]. Luminex HLA Class I and II 
single antigen beads and Fusion analysis (LabScreen, One 
Lambda, Canoga Park, CA, USA) were used to determine 
HLA antibody specificities. HLA antibodies with ≥1000 
normalized mean fluorescence intensity (MFI) was con-
sidered positive. cPRA was determined using HLA 
frequencies from United Network for Organ Sharing 
(UNOS) based on a recent cohort of deceased donors.
Desensitization protocol and outcome measures
A modified version of the high-dose IVIG and rituxi-
mab protocol previously reported by Vo and Jordan was 
used [23]. All candidates were treated with monthly 
IVIG at 2  g/kg, maximum dose 140  g, prior to single-
dose rituximab 375  mg/m2 intravenously administered 
either after the first or sixth dose of IVIG. Re-dosing of 
rituximab was based on measurement of any detect-
able B cells by quantitative flow cytometry on peripheral 
blood. One candidate (C-07) received a second dose of 
rituximab based on the blood incompatible protocol. If 
there was no change in cPRA after 6–12 months of IVIG 
and rituximab, candidates were treated with bortezomib 
1.3  mg/m2 intravenously every 72  h for four doses and 
plasmapheresis for 1–2 cycles following a modified pro-
tocol previously reported by Woodle [24].
Response to therapy was assessed by a decrease of 5% 
points or greater in cPRA. This threshold was based on 
published clinical studies and transplant data that con-
cluded a 5% point decrease in cPRA is clinically relevant 
and corresponds to a significant decrease in HLA anti-
body strength to enable transplantation with a compat-
ible donor by increasing the potential donor pool [2, 25, 
26]. In our study, this decrease in cPRA corresponded to 
a decrease in the strength of two or more HLA antibodies 
in responders. Non-response was defined as no decrease 
in HLA antibodies as measured by cPRA after all desen-
sitization therapies were completed. Candidates who 
received transplants were treated with anti-thymocyte 
globulin (ATG) induction therapy and mycophenolate 
mofetil (MMF), tacrolimus and prednisone for mainte-
nance immunosuppression.
Sample collection and processing
Serial samples of peripheral blood were collected to 
follow B cell immune repertoires pre-treatment, after 
desensitization therapy and after transplantation. Sam-
ples from controls were previously obtained. Peripheral 
blood mononuclear cells (PBMC) for immunoglobulin 
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Fig. 1 Candidate groups and schematic for desensitization protocol
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and cryopreserved in the Human Immune Monitor-
ing Center (HIMC) at Stanford University as previously 
described [27]. RNA was extracted using a Qiagen All-
Prep Kit and quantitated using Bioanalyzer and Quibit 
(Additional file 1: Table S2).
Immunoglobulin sequencing
Immunoglobulin RNA molecules were converted into 
Illumina sequencing libraries using a 5′RACE based assay 
with reverse transcription primed from one of five iso-
types (IgD, IgM, IgA, IgG or IgE) constant regions and 
template-switching enzyme (Superscript II, Invitrogen 
18064-014) that incorporates an oligo containing a ran-
dom 9-mer molecular tag and partial Illumina adapter to 
the 5′ end of each cDNA molecule (ImmuMetrix, LLC; 
Additional file 1: Table S3, Additional file 2). Subsequent 
rounds of PCR amplification incorporate full sequenc-
ing adaptors, including a barcode specific to the sample 
for de-multiplexing pooled sequencing data. Libraries 
from 81 samples were constructed and sequenced on an 
Illumina MiSeq instrument with 2 ×  150  bp chemistry, 
yielding a median sequencing depth of ~70 k B cell reads 
per sample (Additional file 1: Table S2 for details).
Data analysis
We analyzed V gene usage, mutation rates, abundance 
and CDR3 lengths in candidates undergoing desensitiza-
tion therapy and transplantation. Sequenced reads were 
passed through a custom analysis pipeline in order to 
identify isotype composition, gene segment usage and 
point mutations from germline. First, reads were segre-
gated by identical 9 mer barcodes, which were then clus-
tered to distinguish different molecules tagged with the 
same barcode. PCR duplicates and sequencing errors 
were removed by constructing a consensus sequence 
within each cluster using either the majority base or the 
base with the highest quality score when only two reads 
were present. The raw sequence was used for clusters 
containing a single read. These high-quality sequences 
were then aligned using Smith–Waterman sequence 
alignment to the constant region and V, D and J germline 
gene segments as defined in the IMGT immunoglobulin 
database [28]. Somatic hypermutation was estimated by 
dividing the total number of mismatches (relative to the 
corresponding IMGT reference sequences) in the leader 
sequence and partially sequenced V region by the length 
of these regions sequenced (Additional file  2). In order 
to correct for small biases in the mutation frequency 
between sequencing runs, the average mutation fre-
quency across all samples in a sequencing run was sub-
tracted from the average across all lanes. This difference 
was then applied as a correction factor to each sample in 
that lane (see Additional file 1: Table S4 for details).
Features of the immune repertoire, including V gene 
usage, relative isotype distribution and V gene region 
mutation frequency, were determined using programs in 
C++, bash and R. Sequence abundance, isotype compo-
sition and mutation frequency were reported after sub-
sampling the data to 1000 molecules, and significance of 
the results were confirmed at multiple depths including 
no subsampling. Average isotype abundance and muta-
tion frequency were weighted by the number of mol-
ecules in each of the four isotypes IgG, IgA, IgM and IgD. 
Switched isotypes refer to IgG and IgA and non-switched 
isotypes to IgM and IgD. The fraction of IgE molecules 
Table 1 Candidate demographics, cPRA and  clinical out-
comes
SLE systemic lupus erythematosus, PKD polycystic kidney disease, DD deceased 







Age (years) 45 ± 11 40 ± 12 43 ± 7
Male/female 4/3 7/4 2/6
Race
 White 3 3 4
 Black 1 3 1
 Hispanic 1 1 3









 SLE 1 3 1
 PKD 0 1 1
 Congenital 0 3 0




13 ± 16 97.4 ± 2.7 100 ± 0
 After desensiti-
zation
N/A 87.9 ± 3.8 100 ± 0







0 3 (27) 1 (33)
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was low (<1% of molecules) in all samples and was omit-
ted from the analysis. Changes in number of sequences, 
isotype distribution and mutation frequency after IVIG, 
rituximab and transplantation were determined by sub-
tracting the frequency determined in the sample follow-
ing therapy from the frequency prior to therapy. V gene 
usage in pre-treatment samples from the three groups 
(responders, non-responders and controls) was deter-
mined by averaging the molecule abundance of each V 
gene from all the candidates. The relative usage of differ-
ent V-J gene combinations (44 V genes × 6 J genes = 264) 
was compared by determining the relative fraction of 
molecules in each combination and calculating the cor-
relation coefficient between all pairs of candidates.
Significance tests to assess changes after treatment 
were performed in R using the paired Wilcoxon–Mann–
Whitney test. For pre-treatment comparisons among 
the three groups, significance was determined using 
Kruskal–Wallis one-way analysis of variance test. p val-
ues less than 0.05 were confirmed by bootstrapping with 
1000 iterations of the test applied to random samples 
drawn from the data. To determine which of the three 
groups is significantly different from the others, the 
Nemenyi test was applied (kruskalmc function in R) and 
comparisons with p value <0.05 were reported.
Samples from three groups (responders, non-respond-
ers and controls) were evaluated in four phases: (1) pre-
treatment, (2) after IVIG, (3) after rituximab and (4) 
after transplantation. The samples collected from each 
candidate and relative timing of therapies and trans-
plantation are detailed in Fig.  1 and Additional file  1: 
Table S2. For the pre-treatment analysis, 21 candidates 
from all three groups had baseline samples available. To 
assess the effect of IVIG alone, nine candidates had sam-
ples available before and after IVIG alone (dashed line 
in Fig. 1). In candidates receiving IVIG, the sample prior 
to rituximab was compared to the pre-treatment sam-
ple. To assess the effect of rituximab, 19 candidates who 
had samples before and after rituximab were included. 
Included in this analysis were two candidates (R-04 and 
R-09) who received a single dose of bortezomib within 
2  weeks of receiving rituximab and two controls (C-01 
and C-06) who received a single dose of rituximab as 
part of a blood group incompatible protocol. The effects 
of transplantation were evaluated in 10 of 13 candidates 
receiving a transplant. Three candidates (C-05, C-06 and 
C-07) were excluded due to receiving rituximab within 
30  days prior to transplantation; samples from two of 
these candidates (C-06 and C-07) contributed to other 
analyses. We performed the post-transplant analysis with 
the three candidates included and found no significant 
differences in our results. In addition to these 13 candi-
dates, six responders and two non-responders received 
transplants after sample collection was completed (see 
Additional file 1: Table S2).
Results
Candidate characteristics
Demographic, clinical characteristics, cPRA and clinical 
outcomes of the candidates are summarized in Table  1. 
Eleven responders had a decrease in cPRA (range 5–13% 
with mean 9.5  ±  2.3%) and received transplants after 
desensitization therapy. Three non-responders received 
transplants from HLA-matched donors, and five failed to 
receive transplants.
Baseline B cell repertoires
To determine if highly sensitized candidates had a domi-
nant circulating B cell clone that may be responsible for 
producing HLA antibodies, we compared the abundance 
of the top clone in pre-treatment samples from six con-
trols (C), seven non-responding (N) and eight respond-
ing (R) candidates (Fig.  2a). Most samples regardless 
of sensitization status contained similar distributions 
with maximum clone sizes of <3% except for two outli-
ers containing dominant clones of 20% and 6.9% in C 
and R groups, respectively. After subsampling to 1000 
molecules, the fraction of unique sequences was not sig-
nificantly different between the three groups, ranging 
between 0.70 and 0.92 for 18 out of 21 samples (Fig. 2b). 
The two lowest fractions in the R group were from sam-
ples with the two lowest numbers of input molecules, 
arguing against any potential trend for lower sequence 
diversity in non-responders and responders relative to 
controls. The distribution of CDR3 lengths (Fig. 2c) was 
similar in the three groups with nearly identical average 
lengths (58.3–59.3  bp) and standard deviations (10.0–
10.3 bp). The average V gene usage was not significantly 
(See figure on next page.) 
Fig. 2 Baseline B cell repertoires. Baseline B cell repertoires in six control, seven non-responding and eight responding candidates prior to receiving 
desensitization therapy. a The fraction of molecules corresponding to the most abundant sequence. b The fraction of unique sequences detected 
after subsampling to 1000 molecules in each sample. c Histogram of in-frame CDR3 lengths averaged over the samples in each group. d V-gene 
usage averaged across samples in each group. e Cross correlation matrix of the abundances in all V-J gene combinations between all samples 
(individual elements above the diagonal) and averaged within each group (large regions below diagonal). f Molecule-weighted isotype abundance 
in each sample. g Fraction of molecules in each sample containing a switched isotype (i.e., sum of IgG and IgA from d). h Molecule-weighted muta-
tion frequency for each isotype. i Mutation frequency averaged across isotypes for each sample (data from f)
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different between the three groups (Fig.  2d). A more 
detailed comparison based on the cross-correlation of 
the different V-J gene abundances in each sample also 
did not distinguish any differences when visualized indi-
vidually (elements above the diagonal in Fig. 2e) or aver-
aged within each group (elements below the diagonal in 
Fig. 2e).
The relative isotype abundance for each sample 
(Fig.  2f ) was similar for the three groups with elevated 
IgA and IgM (median fractions of 0.54 and 0.26, respec-
tively) and lower IgG and IgD (median fractions of 0.11 
and 0.05, respectively). Candidates responding to therapy 
had significantly lower fractions of IgM (p < 0.05) com-
pared to non-responders and a trend towards lower IgD 
and higher IgA and IgG (Fig. 2f ). To further confirm this 
finding, we combined switched isotypes (IgG and IgA) 
and detected a small increase in the fraction of the com-
bined switched isotypes from 0.67 to 0.73 in respond-
ers compared to non-responders (p < 0.05; Fig. 2g). The 
fraction of switched isotypes in controls was not signifi-
cantly different from either responders or non-respond-
ers (Fig. 2g). V region mutation frequencies were similar 
in the three groups with IgG and IgA approximately 0.07 
mismatches per base compared with 0.045 mismatches 
per base for IgM and IgD (Fig. 2h). Averaging the muta-
tion frequency across the combined switched isotypes 
did not show any significant differences (Fig. 2i).
Peripheral B cell percentages at baseline were sufficient 
and not significantly different between responders and 
non-responders (mean B cell percentage of total lympho-
cytes 6.8 ± 3.8%) and were also similar to B cell percent-
ages in healthy controls as shown in a previous analysis 
[29].
B cell repertoires after IVIG
Nine out of 19 highly sensitized candidates (five respond-
ers and four non-responders) had samples available 
before and after receiving IVIG alone. The median frac-
tion of unique sequences of 0.81 at the pre-treatment 
time point was not significantly different from 0.84 after 
IVIG (Fig. 3a). The median abundance of molecules con-
taining switched isotypes was constant at 0.67 before 
and after IVIG (Fig.  3b). The median mutation fre-
quency in switched and non-switched molecules was also 
unchanged at approximately 0.07 and 0.04 mismatches 
per base, respectively (Fig. 3c). See Additional file 3: Fig-
ure S1a, b for individual isotype abundance and mutation 
frequencies.
B cell repertoires after rituximab
Nineteen out of 26 candidates (eight non-responders, 
nine responders and two controls) had samples avail-
able before and after receiving rituximab. Rituximab 
reduced the median fraction of unique sequences by 40% 
across all candidates with only one candidate experienc-
ing a small increase (p < 0.0005; Fig. 4a). The magnitude 
of the decrease was not significantly different between 
responders and non-responders (Fig.  4b). After rituxi-
mab, the fraction of switched isotypes increased signifi-
cantly from a median of 0.65–0.95 (p < 0.0005; Fig. 4c). 
There was a trend towards a smaller increase in switched 
isotypes in responders (median increase 0.14) compared 
to non-responders (median increase 0.23); however, 
the difference was not significant (p  =  0.09; Fig.  4d). 
The mutation frequency of switched isotypes increased 
in 14 out of 19 candidates with a small increase in the 
median from 0.065 to 0.070 mismatches per base 




Fig. 3 B cell repertoires after IVIG. B cell repertoires after IVIG in 
four non-responding and five responding candidates following the 
pre-treatment sample and ending with the sample immediately prior 
to receiving rituximab. a The fraction of unique sequences detected 
after subsampling to 1000 molecules. b The relative abundance of 
switched isotypes. c Switched and non-switched V-gene mutation 
frequency. Samples from the same candidate are connected by a gray 
line
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non-switched isotypes increased by nearly twofold from 
0.038 to 0.075 mismatches per base (p < 0.0005; Fig. 4e). 
There was a trend towards a larger increase in the non-
switched mutation frequencies in responders (median 
increase 0.031) compared to non-responders (median 
increase 0.054) but the difference was not significant 
(Fig. 4f ).
Immediately after rituximab, peripheral B cells were 
undetectable in all candidates. Approximately half of 
post-rituximab samples were collected within 31 days of 
therapy, and all but one sample from the other half were 
collected within 54  days. Comparing these two groups, 
there was a small but not statistically significant increase 
in the magnitude of the change in isotype abundance and 
class-switched mutation frequency in samples collected 
more than 31  days after transplantation (see Additional 
file 4: Figure S4a, b).
Two candidates also received bortezomib during the 
same period as rituximab (black symbols in Fig. 4a; Addi-
tional file  1: Table S2). One candidate (R-04) showed a 
small increase in unique sequences, and the other can-
didate (R-09) showed a decrease in unique sequences 
similar to the majority of the candidates (Fig.  4a). Prior 
to receiving bortezomib, R-04 was an outlier with a low 
abundance of switched molecules (0.07) relative to the 
other candidates (see Additional file  3: Figure S1c, d). 
However, despite this lower initial abundance of switched 
isotypes, the fraction of unique sequences increased after 
rituximab consistent with the other candidates (Fig. 4a).
B cell repertoires after kidney transplantation
Ten candidates (four controls, five responders and one 
non-responder) had samples available shortly before and 
after kidney transplantation. Six of the ten candidates 
received rituximab more than 30  days prior to receiv-
ing the transplant whereas the remaining four did not 
receive rituximab. The fraction of unique sequences 
increased in eight out of ten candidates from a median 
fraction of 0.87 before transplant to 0.93 after trans-
plant but was not significant (Fig.  5a). The two can-
didates (R-01 and R-11) who showed a decrease in 
unique sequences also had the lowest fraction of unique 
sequences prior to transplantation (0.53 and 0.43, 
respectively). After transplantation, the change in abun-
dance of individual isotypes showed significant increases 
in IgM and IgD (p < 0.05), a decrease in IgA (p < 0.05), 
and a trend towards decreasing IgG (p  =  0.10; Addi-
tional file 3: Figure S1e, f ). Consistent with these obser-
vations, the switched isotype abundance decreased from 
a median of 0.71 to 0.28 after transplantation (p < 0.05; 
Fig.  5b). The mutation frequency of switched isotypes 
(~0.07 mismatches per base) was not significantly dif-
ferent after transplantation, whereas the mutation 
frequency of non-switched isotypes decreased from 0.41 
to 0.33 mismatches per base (p < 0.005; Fig. 5c).
In post-transplant samples from our previous analysis, 
there was repopulation of B cells to levels close to base-
line, which is consistent with findings from other studies 
[29, 30]. Post-transplant samples were collected between 
five and 70 days following transplantation. There was no 
significant impact in the change in isotype abundance or 
mutation frequency based on sampling interval although 
two of the three candidates with increased class-switched 
isotype abundance following transplantation were col-
lected approximately 10  days earlier than the other 
samples, suggesting that these outliers may partly be 
explained by sampling at an earlier time after transplan-
tation. All candidates show a decrease in non-switched 
mutation frequency after transplantation regardless of 
sampling interval (see Additional file 4: Figure S4c, d).
Discussion
In this study we developed a high-throughput DNA 
sequencing assay to measure circulating B cell reper-
toires in highly HLA-sensitized kidney transplant candi-
dates undergoing desensitization therapy to lower HLA 
antibodies and enable transplantation. We hypothesized 
that measuring circulating B cell repertoires could help 
identify which candidates will respond to desensitization 
therapy. cPRA is a measure of sensitization based on pre-
existing HLA antibody specificities and strength in com-
bination with the frequency of HLA antigens in the donor 
population. Since cPRA also represents the probability 
of receiving a compatible transplant, this measurement 
is often used to determine success of desensitization 
therapy [23, 31]. We assessed “response” to therapy as a 
clinically meaningful and durable decrease in cPRA of 5% 
points or greater based on literature and transplant out-
comes data [2, 26].
We first compared B cell repertoires in pre-treatment 
samples in three groups: sensitized candidates who 
responded to desensitization therapy, sensitized candi-
dates who did not respond to desensitization therapy, 
and control candidates with low to moderate levels of 
HLA sensitization. Our results do not identify a single 
dominant B cell clone circulating in highly sensitized 
candidates compared to controls, but we cannot rule out 
the presence of one or more smaller clones that may be 
responsible for producing HLA antibodies. The analysis of 
several different metrics including the fraction of unique 
sequences, CDR3 length, V gene and V-J gene abun-
dances, and isotype mutation frequencies argues against 
a common feature of the repertoire that predisposes can-
didates to high levels of HLA antibody production. Pos-
sible explanations are that the B cell clones circulate at 
low levels in the peripheral blood or the presence of more 
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dominant B cells makes it difficult to detect by our assay. It 
has been suggested that no more than 2% of all B cells are 
present in the peripheral blood compared to the lymph 
nodes, spleen and bone marrow [32], and the relevant 
HLA-specific B cell clones may be sequestered in another 




Fig. 4 B cell repertoires after rituximab. B cell repertoires after rituximab in two controls, eight non-responders (N) and nine responders (R) before 
and after rituximab. a The fraction unique sequences detected in each sample after subsampling to 1000 molecules. b The change in the fraction 
of unique sequence in the N and R groups. c The relative abundance of molecules with switched isotypes. d The change in abundance of the N and 
R groups. e Mutation frequency for switched and non-switched isotypes. f The change in non-switched mutation frequency for N and R groups. 
Samples from the same candidate are connected by a line
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Before desensitization therapy, responders had a 
slightly higher fraction of switched (IgG and IgA) iso-
types compared to non-responders, but without a cor-
responding increase in mutation frequency. This shift 
may represent more memory B cells or plasmablasts in 
the circulation prior to therapy although the relatively 
small magnitude of the change would need to be vali-
dated in a larger study. Memory B cells are thought to 
be important in HLA sensitization as they can quickly 
transform into antibody-secreting plasma cells upon re-
exposure to alloantigen [33]. Thus, depleting these circu-
lating memory B cells may reduce the number of plasma 
cells, and ultimately, the production of high affinity HLA 
antibodies.
We next analyzed changes in the B cell repertoires after 
desensitization therapy. After multiple doses of IVIG, we 
did not detect any changes in the B cell repertoire. IVIG 
is purified immunoglobulin products derived from pooled 
human plasma from thousands of donors and typically con-
tains more than 95% unmodified IgG and trace amounts of 
IgA or IgM [34]. IVIG has been used in transplantation to 
decrease HLA antibodies in order to help enable transplan-
tation in highly sensitized patients [23]. The mechanism is 
largely unknown but may involve binding to Fc receptors 
on immune cells, inhibiting IgG production or inducing B 
cell apoptosis [35]. Our results suggest that IVIG inhibits 
IgG without reducing the number of B cells, although mod-
est depletion of B cells may not be detected by our assay.
After rituximab, the changes in B cell repertoires were 
pronounced with significant decreases in the fraction of 
unique sequences, which is consistent with studies show-
ing a long-lasting reduction in B cells after rituximab [36]. 
We also observed an increase in switched isotypes after 
rituximab, with more than half of candidates’ repertoires 
containing 90% switched molecules. The mutation fre-
quency of the switched molecules increased slightly after 
rituximab, but the mutation frequency in the remain-
ing non-switched molecules increased substantially to 
levels comparable to the switched molecules. Our study 
was not large enough to determine the precise temporal 
dynamics of the repertoire change in each candidate fol-
lowing rituximab therapy. Other work reported that B 
cell depletion persists for more than 180  days following 
treatment [36]. All but one of the post-rituximab sam-
ples was collected within 60 days following therapy with 
no significant differences in class-switched abundance or 
mutation frequency between samples collected within 
this interval. If the peak response following rituximab 
occurs after 60 days or later, our findings, which include 
many samples collected in the first 30 days, may underes-
timate the magnitude of the response. Larger studies are 
required to further characterize the individual variability 
in response after rituximab.
Rituximab, a chimeric CD20 monoclonal antibody, is 
postulated to decrease the production of HLA antibod-
ies through targeting memory and naïve B cells without 
having any known effect on plasmablasts or plasma B 
cells, which do not express CD20 [36, 37]. Our findings 
may suggest an increase or a persistence of memory B 
cells or plasmablasts after rituximab. These results are 
consistent with other work showing that rituximab can 
effectively decrease memory B cells, but the relative 
fraction of memory B cells in both peripheral blood 
and lymph nodes can also increase [36, 38]. In addi-




Fig. 5 B cell repertoires after transplantation. B cell repertoires after 
transplantation in four controls and five responding candidates 
before and after transplantation. a The number of unique sequences 
after subsampling to 1000 molecules. b The fraction of molecules 
corresponding to switched isotypes. c The mutation frequency in 
switched and non-switched isotypes. Samples from the same candi-
date are connected by a line
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unmutated naïve B cells over class-switched mutated 
cells of the IgG and IgA isotypes [36–38]. However, we 
did not find any significant differences in B cell reper-
toires between responders and non-responders after 
rituximab therapy. Similar work in a B cell mediated 
neuropathy was able to identify differences in abun-
dance, mutation frequencies and persistent clones in B 
cell repertoires between patients that did and did not 
respond to rituximab [39].
In the two candidates who received bortezomib close 
to rituximab, one showed changes similar to the other 
candidates receiving rituximab, whereas the other can-
didate showed little change. Bortezomib, a proteasome 
inhibitor, results in apoptosis of plasma cells although 
the effect on memory B cells is unknown [24, 40]. In this 
limited analysis, we were unable to detect any additional 
effect of bortezomib in these two candidates, but larger 
studies are needed to confirm these preliminary findings.
Kidney transplantation and the accompanying immu-
nosuppression resulted in the opposite effect on the B 
cell repertoires as rituximab. We interpret the increasing 
fraction of unique sequences, reduction in the abundance 
of switched isotypes and strong decrease in mutation 
frequency within non-switched isotypes as representing 
the repopulation of naïve B cells after transplantation and 
immunosuppression. It is possible that we are underes-
timating the magnitude of these effects since the four 
candidates that did not receive rituximab experienced 
larger changes than those that received rituximab. The 
sampling interval does not appear to affect the change in 
class-switched mutation frequency following transplan-
tation with the exception of two post-transplant sam-
ples, showing a small increase in class-switched isotype 
abundance, which were collected approximately 10 days 
earlier than the others. At the time of transplantation, all 
candidates receive ATG, which depletes T cells and leads 
to apoptosis of many B cell lineages without a measurable 
effect on peripheral B cell counts [30, 41, 42]. Reducing T 
cells may indirectly lower the mutation frequency since 
helper T cells are required for activating naïve B cells and 
triggering affinity maturation. Although MMF inhibits B 
cell proliferation with therapeutic uses in autoimmune 
disease, the exact effect on different B cell populations 
after transplantation is unknown [43].
Strengths of this study include the single study design 
that allows uniform and longitudinal desensitization pro-
tocols and sample processing as well as prospective and 
consistent HLA antibody monitoring. Another strength 
is our assay, which can detect ample B cell transcripts 
even after depletion by rituximab and can measure iso-
type classes after IVIG infusions, which interfere in 
serum immunoglobulin measurements. The assay imple-
ments bulk repertoire sequencing from total RNA, which 
yields isotype information and a robust signal due to 
multiple RNA copies per cell. Variability in RNA expres-
sion levels between cells, however, has the negative effect 
of complicating estimates of cellular clonality. Using total 
RNA simplifies the workflow, is faster, and reduces cost 
compared with sorted cells, but some cell types are not 
distinguished, such as plasmablasts and memory B cells. 
Both of these cell types are class-switched with elevated 
mutation frequencies, but plasmablasts secrete antibod-
ies whereas memory B cells do not.
Conclusions
This study demonstrates the application of high through-
put sequencing technology to longitudinally monitor B 
cell repertoires in a challenging clinical setting of highly 
HLA-sensitized kidney transplant candidates. We dem-
onstrate that B cell repertoires are dramatically affected 
by rituximab and transplantation with no observed 
changes after IVIG. We detected small differences at 
baseline that may distinguish responders from non-
responders, and larger, prospective studies are required 
to validate these findings. This work builds on our mul-
tivariate analysis model reporting that differences in 
immune and gene profiles may help differentiate candi-
dates that respond to desensitization therapy [29].
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